According to the Government of Delhi in last 24 hours Delhi reports 4,906 new coronavirus (COVID-19) cases, and total number of deaths are 68 deaths.
The total cases from the time of COVID-19 outbreak Delhi has reported 5,66,641 and total recoveries are 5,22,491.The totall number of deaths are 9,066 and active cases are 35,091.
In a Press briefing by Adar Poonawalla, CEO, Serum Insititute of India has said “Vaccine will be distributed initially in India, then we will look at the COVAX countries which are mainly in Africa. The UK & European markets are being taken care of by AstraZeneca & Oxford. Our priority is India & COVAX countries.”
On emergency license for manufacturing of COVID-19 vaccine COVISHIELD, he said “We are in the process of applying for emergency use authorization of Covishield in the next two weeks.”
Wacth Prime Minister reviews Covid-19 vaccine development at Zydus cadila facility in Ahmedabad
Maulana Azad Medical College (MAMC)has issued a notice reopen the Medical Institute by December 1.The institute has used notice after receiving the recommendations from apex medical regulator, National Medical Commission(NMC) recent to reopen medical colleges on or before 1st December2020.But it’s important for the college follow the SOPs and the guidelines issued by the Central and State governments with regards to be taken for the prevention of COVID-19 infection. It’s important for even parents to check the website of college to know about the instructions to followed and about the re-join of college.
According to the advisory issued by the National Medical Commission (NMC) “It is further advised that all medical colleges/institutions shall ensure strict compliance of guidelines issued by the Ministry of Health Ministry Welfare State/UT Government about COVID-19 preventive measures including social distancing, use of mask and sanitization measure of hostels, class, laboratories , lecture theatres, spaces, etc.”
Prime Minister Narendra Modi to visit three cities on November 28 to “personally review the Coronavirus vaccine development and manufacturing process”, said Prime Minister’s Office.
He will be visiting Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad and Serum Institute of India in Pune.
“As India enters a decisive phase of the fight against COVID-19, PM Modi’s visit to these facilities and discussions with the scientists will help him get a first-hand perspective of the preparations, challenges, and roadmap in India’s endeavor to vaccinate its citizens,” said PMO in an official statement.
The AstraZeneca – Oxford vaccine is safe and effective says the statement released by AstraZeneca. The giant and one of the leading company has admitted to its dosing error. The partnered company Serum Institute of India (SII) for trials in India has said that vaccine candidates are safe and vaccine trials are running smoothly with strict adherence to all the necessary protocols in India there is no need to panic.
“The AstraZeneca-Oxford vaccine is safe and effective. Even the lowest efficacy results are at 60-70%, making it a viable vaccine against the virus. That said, varied age groups with different dosage forms will result in slight variations and efficacy. We must be patient and not panic. The Indian trials are running smoothly with strict adherence to all the necessary processes and protocols. So far, there are no concerns. However, we are going through the data that is available and will make a further statement, if needed.” Pune based Serum Insitute of India said in a statement
During a news conference the British government’s Chief Scientific Adviser Patrick Vallance said AstraZeneca Covid-19 vaccine against the that it worked , he answered to this when asked about doubts that have been raised about the vaccine.
The information has been shared by the news agency Reuters.
All India Institute of Medical Sciences (AIIMS) Delhi has started clinical trials of Bharat BioTech’s indigenous Covid-19 vaccine COVAXIN on humans from today.
A new study would be done to evaluate a lower dosage that performed better than higher dose in AstraZeneca’s studies, that will be an additional global trial to assess the efficacy of its COVID-19 vaccine. AstraZeneca’s, Chief Executive Pascal Soriot has been quoted saying this to the Bloomberg media.
According to the Bloomberg News report, Soriot said the efficacy of the vaccine is high so the global trial will be done on the less patients “International study, but this one could be faster because we know efficacy is high so we need a smaller number of patients.”
All India Syringe and Needle Manufacturers Association (AISNMA) who is the Nodal Associaton for Syringes Manufacturers of India with 18 members from all geographical corners of the country has written a letter to Prime Minister Narendra Modi regarding the capacity for Syringes used for Covid-19 vaccination. They have pledged their full support for the vaccination drive nationwide against the novel Coronavirus(COVID-19).
The association has offered an uncommitted capacity of over 350 million syringes per month.
They have also written a letter to the Union Ministry of Health and Family Welfare regarding stockpile and clarity on quantity “We are in touch with MOH&FW to initiate a stockpile and have sought clarity on quantity, timelines, and specifications sought by them so that supplies can match demand,” the letter notes